Sociedad Española de Oncología Médica (SEOM). Las cifras del cáncer en España; 2024.
Rao G, Crispens M, Rothenberg ML. Intraperitoneal chemotherapy for ovarian cancer: Overview and perspective. J Clin Oncol 2007;25:2867-72.
DOI: 10.1200/JCO.2007.10.8167
Markman M. Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity.Cancer Treat Rev 1986;13:219-42.
DOI: 10.1016/0305-7372(86)90007-1
McClay EF, Howell SB. A review:Intraperitoneal cisplatin in the management of patients with ovarian cancer. Gynecol Oncol 1990;36:1-6.
DOI: 10.1016/0090-8258(90)90099-7
Markman M, Francis P, Rowinsky E, et al. Intraperitoneal pacli- taxel: A possible role in the management of ovarian cancer? Semin Oncol 1995;22(Suppl.6):84-7.
Markman M, Reichman B, Hakes T, et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: Influence of a prior response to intravenous cisplatin. J Clin Oncol 1991;9:1801-5.
DOI: 10.1200/JCO.1991.9.10.1801
Recio FO, Piver MS, Hempling RE, et al. Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer. Gynecol Oncol 1998;68:267-273.
DOI: 10.1006/gyno.1998.4940
Barakat RR, Sabbatini P, Bhaskaran D, et al. Intraperitoneal che- motherapy for ovarian carcinoma: Results of long-term follow- up. J Clin Oncol 2002;20:694-8.
DOI: 10.1200/JCO.2002.20.3.694
Bookman MA, Brady MF. Intraperitoneal chemotherapy: long- term outcomes revive a long-running debate. J Clin Oncol 2015;33:1424-1426.
DOI: 10.1200/JCO.2014.60.2797
Zylberberg B, Ravina JH, Salat-Baroux J, et al. Polichemothe- rapy of ovarian cancer via combined iv e ip routes. Technic and preliminary results. J Gynecol Obstet Bio Reprod (Paris) 1986;15:671-6.
Kirmani S, Braly PS, McClay EF, et al. A comparison of intrave- nous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol Oncol 1994;54(3):338-44.
DOI: 10.1006/gyno.1994.1220
Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-5.
DOI: 10.1056/NEJM199612263352603
Polyzos A, Tsavaris N, Kosmas C, et al. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemothe- rapy for stage III ovarian cancer. Oncology 1999;56(4):291-6.
DOI: 10.1159/000011980
Gadducci A, Carnino F, Chiara S, et al. Intraperitoneal vs. iv cisplatin in combination with iv cyclophosphamide and epidoxo- rrubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of Gruppo Oncologico Nord-Ovest. Gynecol Oncol 2000;76:157-62.
DOI: 10.1006/gyno.1999.5677
Yen MS, Juang CM, Lai CR, et al. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int J Gynaecol Obstet 2001;72(1):55-60.
DOI: 10.1016/S0020-7292(00)00340-4
Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus mode- rately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001-7.
DOI: 10.1200/JCO.2001.19.4.1001
Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cis- platin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43.
DOI: 10.1056/NEJMoa052985
Rothenberg ML, Liu PY, Braly PS, et al. Comnined intraperito- neal and intravenous chemotherapy for women with optimally debulked ovarian cancer: Results from an intergroup phase II trial. J Clin Oncol 2003;21:1313-9.
DOI: 10.1200/JCO.2003.07.031
Wenzel LB, Huang HQ, Armstrong DK, et al. Health-Related Quality of Life During and After Intraperitoneal Versus Intra- venous Chemotherapy for Optimally Debulked Ovarian Can- cer: A Gynecologic Oncology Group Study. J Clin Oncol 2007;25:437-43.
DOI: 10.1200/JCO.2006.07.3494
Bookman MA, Greer BE, Ozols RF. Optimal therapy of advan- ced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5. Int J Gynecol Cancer 2003;13(6):735-40.
DOI: 10.1136/ijgc-00009577-200311000-00002
Clinical advisory: NCI issues clinical announcement for prefe- rred method of treatment for advanced ovarian cancer [accessed March 1, 2006]. Available at www.nlm.nih.gov/databases/alerts/ovarian_ip_chemo.html
Tewari D, Java JJ, Salani R, et al. Long-term survival advantage and prognostic fac- tors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2015;33(13):1460-6.
DOI: 10.1200/JCO.2014.55.9898
Jaaback K, Johnson N. Intraperitoneal chemotherapy for the ini- tial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 2006(1):CD005340.
DOI: 10.1002/14651858.CD005340.pub2
Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database of Syst Rev 2016(1):CD005340.
DOI: 10.1002/14651858.CD005340.pub4
Hess LM, Benham-Hutchins M, Herzog TJ, et al. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treat- ment of ovarian cancer. Int J Gynecol Cancer 2007;17(3):561-70.
DOI: 10.1136/ijgc-00009577-200705000-00003
Fujiwara K, Nagao S, Kigawa J, et al. Phase II study of intrape- ritoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Cancer Study Group Study. Int J Gynecol Cancer 2009;19(5):834-7.
DOI: 10.1111/IGC.0b013e3181a29dfe
Walker JL, Brady MF, DiSilvestro PA, et al. A phase III clinical trial of bevacizumab with iv versus ip chemotherapy in ovarian, fallopian tube, and primary peritoneal carcinoma, a GOG/NRG trial (GOG 252). SGO 2016;Abstract 6.
DOI: 10.1016/j.ygyno.2016.04.535
Mackay H, Gallagher CJ, Parulekar WR, et al. OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (ip) versus intravenous (iv) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC). J Clin Oncol 2016;34(Suppl):bstr LBA5503).
DOI: 10.1200/JCO.2016.34.15_suppl.LBA5503
Filis P, Mauri D, Markozannes G, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials. ESMO Open 2022;7(5):100586.
DOI: 10.1016/j.esmoop.2022.100586
Lim MC, Chang S, Park B, et al. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial. JAMA Surg 2022;157(5):374-83.
DOI: 10.1001/jamasurg.2022.0143
Antonio CCP, Alida GG, Elena GG, et al. Cytoreductive Surgery With or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial. Ann Surg Oncol 2022;29:2617-25.
DOI: 10.1245/s10434-021-11087-7
Van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018;378(3):230-40.
DOI: 10.1056/NEJMoa1708618
Díaz-Montes TP, El-Sharkawy F, Gushchin V, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as initial treatment of ovarian, fallopian tube, and pri- mary peritoneal cancer: preliminary results of a phase II randomized clinical trial. Gynecol Oncol 2018;149:35.
DOI: 10.1016/j.ygyno.2018.04.079
Zivanovic O, Chi DS, Zhou Q, et al. Secondary cytoreduction and car- boplatin hyperthermic intraperitoneal chemotherapy for platinum- sensitive recurrent ovarian cancer: an MSK team ovary phase II study. J Clin Oncol 2021;39(23):2594-604.
DOI: 10.1200/JCO.21.00605
Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 2015;22(5):1570-5.
DOI: 10.1245/s10434-014-4157-9
Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-83.
DOI: 10.1056/NEJMoa1104390
Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484-96.
DOI: 10.1056/NEJMoa1103799
Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379(26):2495-505.
DOI: 10.1056/NEJMoa1810858
Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 2019;381(25):2416-28.
DOI: 10.1056/NEJMoa1911361
González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019;381(25):2391-402.
DOI: 10.1056/NEJMoa1910962
Monk BJ, Parkinson C, Lim MC, et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in pa- tients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG- 3020/ENGOT-ov45). J Clin Oncol 2022;40(34):3952-64.
DOI: 10.1200/JCO.22.01003
Número de descargas:
344
Número de visitas:
43
Citas:
0
